Alexion Pharmaceuticals, Inc.

Michael Schilsky

Anna Czlonkowska

Peter Ferenci

Karl-Heinz Weiss

Carl Bjartmar

Peter Hedera

Frederick Askari

Aftab Ala

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

Bis-choline tetrathiomolybdate for treating Wilson Disease

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

Bis-choline tetrathiomolybdate for treating Wilson disease

Growing community of inventors

Stockholm, Sweden

Michael Schilsky